English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy

Power, A., & Bell, J. (2008). Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy. Gene Therapy, 15(10), 772-779. doi:10.1038/gt.2008.40.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/11858/00-001M-0000-0013-C971-E Version Permalink: http://hdl.handle.net/21.11116/0000-0003-309D-6
Genre: Journal Article

Files

show Files

Locators

show
hide
Locator:
https://www.nature.com/articles/gt200840.pdf (Publisher version)
Description:
-

Creators

show
hide
 Creators:
Power, AT1, Author              
Bell, JC, Author
Affiliations:
1External Organizations, ou_persistent22              

Content

show
hide
Free keywords: -
 Abstract: Live cells offer unique advantages as vehicles for systemic oncolytic virus (OV) delivery. Recent studies from our laboratory and others have shown that virus-infected cells can serve as Trojan horse vehicles to evade antiviral mechanisms encountered in the bloodstream, prevent uptake by off-target tissues and act as microscale factories to produce OV upon arrival in tumor beds. However to be employed effectively, OV-infected cells are best viewed as dynamic biological systems rather than static therapeutic agents. The time-dependent processes of infection and in vivo cell trafficking will inevitably vary depending on which particular OV is being delivered, as well as the type of carrier cells (CC) employed. Understanding these parameters with respect to each unique CC/OV combination will therefore be required in order to effectively evaluate and harness their potential in preclinical study. In the following review, we discuss how early studies of OV delivery led us to investigate the use of cell carriers in our laboratory, and the approaches we are currently undertaking to compare the dynamics of different CC/OV systems. On the basis of these studies and others it is apparent that the success of any cell-based system for OV delivery rests upon the coordinated timing of three sequential phases—(1) ex vivo loading, (2) stealth delivery and (3) virus production at the tumor site. While at the current time, the timing of these processes are coupled to the natural cycle of infection and in vivo trafficking properties innate to each cell virus system, a quantitative delineation of their dynamics will lay the foundation for engineering CC/OV biotherapeutic systems that can be clinically deployed in a highly directed and controlled manner.

Details

show
hide
Language(s):
 Dates: 2008-05
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.1038/gt.2008.40
BibTex Citekey: PowerB2008
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Gene Therapy
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Houndmills, Basingstoke, Hampshire, UK : Macmillan Press Ltd.
Pages: - Volume / Issue: 15 (10) Sequence Number: - Start / End Page: 772 - 779 Identifier: ISSN: 0969-7128
CoNE: https://pure.mpg.de/cone/journals/resource/954925583202